anti-CD3/anti-GPRC5D bispecific T-cell engager (Integral Molecular)

N/A

Report date: 2026/03/19 16:53:47

Base Information

Drug Nameanti-CD3/anti-GPRC5D bispecific T-cell engager (Integral Molecular)
Drug Alias Nameanti-CD3/GPRC5D bispecific mAbs (Integral Molecular)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionG-protein coupled receptor family C group 5member D modulatorsT cell surface glycoprotein CD3 modulators
TargetsG-protein coupled receptor family C group 5member DT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntegral Molecular Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntegral Molecular Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A